Lo-Coco, F and Ammatuna E (2006) The biology of acute promyelocytic leukemia and its impact on diagnosis and treatment. Hematology Am Soc Hematol Educ Program 156–61, 514.

Guru Murthy GS et al (2020) Improving outcomes of acute promyelocytic leukemia in the current era: analysis of the SEER database. J Natl Compr Canc Netw 18(2):169–175

PubMed  Google Scholar 

Stahl M, Tallman MS (2019) Acute promyelocytic leukemia (APL): remaining challenges towards a cure for all. Leuk Lymphoma 60(13):3107–3115

Article  PubMed  PubMed Central  Google Scholar 

Kantarjian HM et al (2022) The cure of leukemia through the optimist’s prism. Cancer 128(2):240–259

Article  PubMed  Google Scholar 

Russell N et al (2018) Attenuated arsenic trioxide plus ATRA therapy for newly diagnosed and relapsed APL: long-term follow-up of the AML17 trial. Blood 132(13):1452–1454

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lu J et al (2014) Treatment outcomes in relapsed acute promyelocytic leukemia patients initially treated with all-trans retinoic acid and arsenic compound-based combined therapies. Oncol Lett 7(1):177–182

Article  CAS  PubMed  Google Scholar 

Churpek JE, Larson RA (2013) The evolving challenge of therapy-related myeloid neoplasms. Best Pract Res Clin Haematol 26(4):309–317

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hulegardh E et al (2015) Characterization and prognostic features of secondary acute myeloid leukemia in a population-based setting: a report from the Swedish Acute Leukemia Registry. Am J Hematol 90(3):208–214

Article  PubMed  Google Scholar 

Morton LM et al (2019) Association of chemotherapy for solid tumors with development of therapy-related myelodysplastic syndrome or acute myeloid leukemia in the modern era. JAMA Oncol 5(3):318–325

Article  PubMed  Google Scholar 

Fianchi L et al (2018) Therapy-related myeloid neoplasms: clinical perspectives. Onco Targets Ther 11:5909–5915

Article  CAS  PubMed  PubMed Central  Google Scholar 

Khoury JD et al (2022) The 5th edition of the World Health Organization Classification of haematolymphoid tumours myeloid and histiocytic/dendritic neoplasms. Leukemia 36(7):1703–1719.

Csizmar CM et al (2021) PARP inhibitors and myeloid neoplasms: a double-edged sword. Cancers (Basel) 13(24). https://doi.org/10.3390/cancers13246385

Yin XJ et al (2023) At what point are long-term (>5 years) survivors of APL safe? A study from the SEER database. Cancers (Basel) 15(3). https://doi.org/10.3390/cancers15030575

Guru Murthy GS et al (2018) Incidence and survival of therapy related myeloid neoplasm in United States. Leuk Res 71:95–99

Article  PubMed  Google Scholar 

Latagliata R et al (2002) Therapy-related myelodysplastic syndrome-acute myelogenous leukemia in patients treated for acute promyelocytic leukemia: an emerging problem. Blood 99(3):822–824

Article  CAS  PubMed  Google Scholar 

Lobe I et al (2003) Myelodysplastic syndrome after acute promyelocytic leukemia: the European APL group experience. Leukemia 17(8):1600–1604

Article  CAS  PubMed  Google Scholar 

Batzios C et al (2009) Secondary clonal cytogenetic abnormalities following successful treatment of acute promyelocytic leukemia. Am J Hematol 84(11):715–719

Article  PubMed  Google Scholar 

Montesinos P et al (2010) Therapy-related myeloid neoplasms in patients with acute promyelocytic leukemia treated with all-trans-retinoic acid and anthracycline-based chemotherapy. J Clin Oncol 28(24):3872–3879

Article  CAS  PubMed  Google Scholar 

Sanz MA, Montesinos P (2010) Risk-adapted treatment for low- and intermediate-risk acute promyelocytic leukemia. Clin Lymphoma Myeloma Leuk 10(Suppl 3):S130–S134

Article  PubMed  Google Scholar 

Sanz MA et al (2000) Definition of relapse risk and role of nonanthracycline drugs for consolidation in patients with acute promyelocytic leukemia: a joint study of the PETHEMA and GIMEMA cooperative groups. Blood 96(4):1247–1253

CAS  PubMed  Google Scholar 

Cicconi L et al (2020) Long-term results of all-trans retinoic acid and arsenic trioxide in non-high-risk acute promyelocytic leukemia: update of the APL0406 Italian-German randomized trial. Leukemia 34(3):914–918

Article  PubMed  Google Scholar 

Iyer SG et al (2022) The treatment of acute promyelocytic leukemia in 2023: Paradigm, advances, and future directions. Front Oncol 12:1062524

Article  CAS  PubMed  Google Scholar 

Wang HY et al (2017) Relationship between peripheral blood white blood cell count and early death rate in patients with acute promyelocytic leukemia. Zhongguo Shi Yan Xue Ye Xue Za Zhi 25(3):718–722

PubMed  Google Scholar 

Pei RZ et al (2016) Clinical features and prognostic analysis of high-risk acute promyelocytic leukemia patients. Zhonghua Xue Ye Xue Za Zhi 37(5):360–365

CAS  PubMed  Google Scholar 

Kelaidi C et al (2006) Late first relapses in APL treated with all-trans-retinoic acid- and anthracycline- based chemotherapy: the European APL group experience (APL 91 and APL 93 trials). Leukemia 20(5):905–907

Article  CAS  PubMed  Google Scholar 

Montesinos P et al (2009) Central nervous system involvement at first relapse in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline monochemotherapy without intrathecal prophylaxis. Haematologica 94(9):1242–1249

Article  CAS  PubMed  PubMed Central  Google Scholar 

Fouzia NA et al (2021) Management of relapse in acute promyelocytic leukaemia treated with up-front arsenic trioxide-based regimens. Br J Haematol 192(2):292–299

Article  CAS  PubMed  Google Scholar 

Vahdat L et al (1994) Early mortality and the retinoic acid syndrome in acute promyelocytic leukemia: impact of leukocytosis, low-dose chemotherapy, PMN/RAR-alpha isoform, and CD13 expression in patients treated with all-trans retinoic acid. Blood 84(11):3843–3849

Article  CAS  PubMed  Google Scholar 

Pollyea DA, Bixby D, Perl A et al (2021) NCCN guidelines insights: acute myeloid leukemia, version 2.2021. J Natl Compr Canc Netw 19(1):16–27

Burnett AK et al (2015) Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial. Lancet Oncol 16(13):1295–1305

Article  CAS  PubMed  Google Scholar 

Lancet JE et al (2020) A phase 2 study of ATRA, arsenic trioxide, and gemtuzumab ozogamicin in patients with high-risk APL (SWOG 0535). Blood Adv 4(8):1683–1689

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wang HY et al (2022) An effective and chemotherapy-free strategy of all-trans retinoic acid and arsenic trioxide for acute promyelocytic leukemia in all risk groups (APL15 trial). Blood Cancer J 12(11):158

Article  PubMed  PubMed Central  Google Scholar 

Chendamarai E et al (2015) Comparison of newly diagnosed and relapsed patients with acute promyelocytic leukemia treated with arsenic trioxide: insight into mechanisms of resistance. PLoS ONE 10(3):e0121912

Article  PubMed  PubMed Central  Google Scholar 

Kulkarni U et al (2020) A phase II study evaluating the role of bortezomib in the management of relapsed acute promyelocytic leukemia treated upfront with arsenic trioxide. Cancer Med 9(8):2603–2610

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cassinat B et al (2011) New role for granulocyte colony-stimulating factor-induced extracellular signal-regulated kinase 1/2 in histone modification and retinoic acid receptor alpha recruitment to gene promoters: relevance to acute promyelocytic leukemia cell differentiation. Mol Cell Biol 31(7):1409–1418

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zassadowski F et al (2015) Lithium chloride antileukemic activity in acute promyelocytic leukemia is GSK-3 and MEK/ERK dependent. Leukemia 29(12):2277–2284

Article